ARHGAP19 and endometrial cancer: Mechanistic analyses using endometrial cancer cells (HEC50, AN3CA) showed that tumor-suppressive activities of miRNA200c are executed by suppression of mesenchymal and neuronal genes expression (Rho GTPase activating protein 19 (ARHGAP19), fibronectin 1, moesin, neurotrophic tyrosine receptor kinase type 2, and leptin receptor) that are included in cell motility and anoikis resistance and by targeting ZEB1/2 (facilitates restoration of E-cadherin expression).